Subcutaneously-Administered Infliximab in the Management of Rheumatoid Arthritis: A Short Narrative Review of Current Clinical Evidence

The first subcutaneous (SC) formulation of infliximab CT-P13 has been authorized for the treatment of rheumatoid arthritis (RA) in Europe in 2019. Later, in 2020, approved indications were extended also to ankylosing spondylitis, psoriatic arthritis, psoriasis, Crohn’s disease (CD) and ulcerative co...

Descripción completa

Detalles Bibliográficos
Autores principales: Iannone, Florenzo, Conti, Fabrizio, Cauli, Alberto, Farina, Alberto, Caporali, Roberto
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove 2022
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167594/
https://www.ncbi.nlm.nih.gov/pubmed/35673354
http://dx.doi.org/10.2147/JIR.S240593

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9167594/
https://www.ncbi.nlm.nih.gov/pubmed/35673354
http://dx.doi.org/10.2147/JIR.S240593

Ejemplares similares